

All articles in *Diabetes Care* are available on the World Wide Web at [www.diabetes.org/diabetescare](http://www.diabetes.org/diabetescare). Cover articles (►) and ADA Statements are available free of charge. Other articles are available free to print subscribers or can be purchased as e-prints or reprints.

## Original Research

### Clinical Care/Education/Nutrition/Psychosocial Research

**1891** Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors

L. Randall, J. Begovic, M. Hudson, D. Smiley, L. Peng, N. Pitre, D. Umpierrez, G. Umpierrez

**1897** Development of autoantibodies in the TrialNet Natural History Study

K. Vehik, C.A. Beam, J.L. Mahon, D.A. Schatz, M.J. Haller, J.M. Sosenko, J.S. Skyler, J.P. Krischer, for the TrialNet Natural History Study Group

**1902** Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study

J.I. Barzilay, P. Gao, L. Rydén, H. Schumacher, J. Probstfield, P. Commerford, A. Dans, R. Ferreira, M. Keltai, E. Paolasso, S. Yusuf, K. Teo, on behalf of the TRANSCEND Investigators

**1908** Hemoglobin A<sub>1c</sub> as a screen for previously undiagnosed prediabetes and diabetes in an acute-care setting

R.A. Silverman, U. Thakker, T. Ellman, I. Wong, K. Smith, K. Ito, K. Graff

**1913** Mediterranean diet and type 2 diabetes risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study: the InterAct project

The InterAct Consortium

**1919** Lifestyle counseling for type 2 diabetes risk reduction in Dutch primary care: results of the APHRODITE study after 0.5 and 1.5 years

P.W.A. Vermunt, I.E.J. Milder, F. Wielgaard, J.H.M. de Vries,

H.A.M. van Oers, G.P. Westert

**1926** Peer-led diabetes education programs in high-risk Mexican Americans improve glycemic control compared with standard approaches: a Project Dulce promotoras randomized trial

A. Philis-Tsimikas, A. Fortmann, L. Lleva-Ocana, C. Walker, L.C. Gallo

**1932** Changes in altitude cause unintended insulin delivery from insulin pumps: mechanisms and implications

B.R. King, P.W. Goss, M.A. Paterson, P.A. Crock, D.G. Anderson

**1934** Cluster-randomized trial of a mobile phone personalized behavioral intervention for blood glucose control

C.C. Quinn, M.D. Shardell, M.L. Terrin, E.A. Barr, S.H. Ballew, A.L. Gruber-Baldini

**1943** Short form of the Chinese version Diabetes Quality of Life for Youth scale: a psychometric testing in Taiwanese adolescents with type 1 diabetes

R.-H. Wang, F.-S. Lo, B.-H. Chen, H.-Y. Hsu, Y.-J. Lee

**1946** Novel soy germ pasta improves endothelial function, blood pressure, and oxidative stress in patients with type 2 diabetes

C. Clerici, E. Nardi, P.M. Battezzati, S. Asciutti, D. Castellani, N. Corazzi, V. Giuliano, S. Gaggi, G. Perriello, G. Di Matteo,

F. Galli, K.D.R. Setchell

**1949** Comparison of hemoglobin A<sub>1c</sub> with fasting plasma glucose and 2-h postchallenge glucose for risk stratification among women with recent gestational diabetes mellitus

C. Kim, W.H. Herman, N.W. Cheung, E.P. Gunderson, C. Richardson

### Epidemiology/Health Services Research

**1952** Hemoglobin A<sub>1c</sub>, fasting glucose, and cardiovascular risk in a population with high prevalence of diabetes: the Strong Heart Study

H. Wang, N.M. Shara, E.T. Lee, R. Devereux, D. Calhoun, G. de Simone, J.G. Umans, B.V. Howard

**1959** Cross-sectional and longitudinal changes of glucose effectiveness in relation to glucose tolerance: the Insulin Resistance Atherosclerosis Study

C. Lorenzo, L.E. Wagenknecht, A.J. Karter, A.J.G. Hanley, M.J. Rewers, S.M. Haffner

**1965** Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients

N.E. Morden, S.K. Liu, J. Smith, T.A. Mackenzie, J. Skinner, M. Korc

**1972** Association between type 2 diabetes and exposure to persistent organic pollutants

R. Airaksinen, P. Rantakokko, J.G. Eriksson, P. Blomstedt, E. Kajantie, H. Kiviranta

**1980** Prevalence and management of diabetes and metabolic risk factors in Thai adults: the Thai National Health Examination Survey IV, 2009

W. Aekplakorn, S. Chariyalertsak, P. Kessomboon, R. Sangthong, R. Inthawong, P. Putwatana, S. Taneepanichskul, the Thai National Health Examination Survey IV Study Group

**►1986** Changes in BMI, duration of overweight and obesity, and glucose metabolism: 45 years of follow-up of a birth cohort

C. Power, C. Thomas

**1992** Achieved levels of HbA<sub>1c</sub> and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes Research Network Epidemiology Group

L. Govan, O. Wu, A. Briggs, H.M. Colhoun, C.M. Fischbacher, G.P. Leese, J.A. McKnight, S. Philip, N. Sattar, S.H. Wild, R.S. Lindsay, on behalf of the Scottish Diabetes Research Network Epidemiology Group

**1998** Household income and cardiovascular disease risks in U.S. children and young adults: analyses from NHANES 1999–2008

M.K. Ali, K.M. Bullard, G.L. Beckles, M.R. Stevens, L. Barker,

K.M.V. Narayan, G. Imperatore

**►2005** Decline in the cumulative incidence of severe diabetic retinopathy in patients with type 1 diabetes

J.P. Kyö, V. Harjutsalo, C. Forsblom, K. Hietala, P.A. Summanen,

P.-H. Groop, on behalf of the FinnDiane Study Group

### Emerging Treatments and Technologies

**2008** Effects of the new dual PPAR $\alpha/\delta$  agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism

B. Cariou, Y. Zair, B. Staels, E. Bruckert

**2015** Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

M.A. Nauck, S. Del Prato, J.J. Meier, S. Durán-García, K. Rohwedder, M. Elze, S.J. Parikh

**►2023** Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk

P. Choudhary, J. Shin, Y. Wang, M.L. Evans, P.J. Hammond, D. Kerr, J.A.M. Shaw, J.C. Pickup, S.A. Amiel

**2026** Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients  
N. Giannoukakis, B. Phillips, D. Finegold, J. Harnaha, M. Trucco

## Pathophysiology/Complications

**►2033** Declining  $\beta$ -cell function relative to insulin sensitivity with escalating OGTT 2-h glucose concentrations in the nondiabetic through the diabetic range in overweight youth  
S.F. Burns, F. Bacha, S.J. Lee, H. Tsayli, N. Gungor, S.A. Arslanian

**2041** Effects of exenatide on measures of  $\beta$ -cell function after 3 years in metformin-treated patients with type 2 diabetes  
M.C. Bunck, A. Cornér, B. Eliasson, R.J. Heine, R.M. Shaginian, M.-R. Taskinen, U. Smith, H. Yki-Järvinen, M. Diamant

**2048** Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes  
C. Pennartz, N. Schenker, B.A. Menge, W.E. Schmidt, M.A. Nauck, J.J. Meier

**2054** Efficacy and safety of antioxidant treatment with  $\alpha$ -lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial  
D. Ziegler, P.A. Low, W.J. Litchy, A.J.M. Boulton, A.I. Vinik, R. Freeman, R. Samigullin, H. Tritschler, U. Munzel, J. Maus, K. Schütte, P.J. Dyck

**2061** Gestational diabetes mellitus causes changes in the concentrations of adipocyte fatty acid-binding protein and other adipocytokines in cord blood  
H. Ortega-Senovilla, U. Schaefer-Graf, K. Meitzner, M. Abou-Dakn, K. Graf, U. Kintscher, E. Herrera

**2067** Ratio of waist-to-calf circumference and carotid atherosclerosis in Korean patients with type 2 diabetes  
S.-K. Kim, Y.J. Choi, B.W. Huh, C.-S. Kim, S.W. Park, E.J. Lee, Y.-W. Cho, K.B. Huh

**2072** Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes  
P.C.M. van Poppel, M.G. Netea, P. Smits, C.J. Tack

**2078** Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial  
M.E. Hellemons, F. Persson, S.J.L. Bakker, P. Rossing, H.-H. Parving, D. De Zeeuw, H.J. Lambers Heerspink

**2084** Type 1 diabetes and interferon therapy: a nationwide survey in Japan  
K. Nakamura, E. Kawasaki, A. Imagawa, T. Awata, H. Ikegami, Y. Uchigata, T. Kobayashi, A. Shimada, K. Nakanishi, H. Makino, T. Maruyama, T. Hanafusa, the Research Committee on Type 1 Diabetes of the Japan Diabetes Society

**2090** Observation on renal outcomes in the Veterans Affairs Diabetes Trial  
L. Agrawal, N. Azad, N.V. Emanuele, G.D. Bahn, D.G. Kaufman, T.E. Moritz, W.C. Duckworth, C. Abraira, for the Veterans Affairs Diabetes Trial (VADT) Study Group

## Cardiovascular and Metabolic Risk

**2095** Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: a report from the Swedish National Diabetes Register  
B. Eliasson, J. Cederholm, K. Eeg-Olofsson, A.-M. Svensson, B. Zethelius, S. Gudbjörnsdóttir, on behalf of the National Diabetes Register

**2101** Cardiovascular risk prediction is improved by adding asymptomatic coronary status to routine risk assessment in type 2 diabetic patients  
E. Cosson, M.T. Nguyen, B. Chanu, I. Banu, S. Chiheb, C. Balta, K. Takbou, P. Valensi

**2108** Two-step approach for the prediction of future type 2 diabetes risk  
M.A. Abdul-Ghani, T. Abdul-Ghani, M.P. Stern, J. Karavci, T. Tuomi, I. Bo, R.A. DeFronzo, L. Groop

**2113** High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects  
C. Chen, B.M.Y. Cheung, A.W.K. Tso, Y. Wang, L.S.C. Law, K.L. Ong, N.M.S. Wat, A. Xu, K.S.L. Lam

## Reviews/Commentaries/ADA Statements

### 2116 Meta-analysis

Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies  
J.-Y. Dong, P. Xun, K. He, L.-Q. Qin

### 2123 Consensus Report

The Charcot foot in diabetes  
L.C. Rogers, R.G. Frykberg, D.G. Armstrong, A.J.M. Boulton, M. Edmonds, G. Ha Van, A. Hartemann, F. Game, W. Jeffcoate, A. Jirkovska, E. Jude, S. Morbach, W.B. Morrison, M. Pinzur, D. Pitocco, L. Sanders, D.K. Wukich, L. Uccioli

## Editorials

### 2130 Editorial (see Kytö et al., p. 2005)

Time for a victory lap or time to raise the levees: a perspective on complication reduction and new-onset diabetes  
J.S. Wrobel, G.E. Reiber

### 2133 Editorial (see Bunck et al., p. 2041)

Incretin-based therapy and the quest for sustained improvements in  $\beta$ -cell health  
D.J. Drucker

### 2136 Editorial (see Choudhary et al., p. 2023)

Closing the loop: another step forward  
R.S. Weinstock

### 2138 Withdrawn

### 2139 Issues and Events

## Diabetes Care Electronic Pages

Available at <http://care.diabetesjournals.org>

## Perspectives on the News

**e140** World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease: part 3  
Z.T. Bloomgarden

## Online Letters: Observations

**e146** Insulin autoimmune syndrome induced by  $\alpha$ -lipoic acid in a Caucasian woman: case report  
E. Bresciani, A. Busi, E. Bazzigaluppi, G. Balestrieri

**e147** Vitamin K2 supplementation improves insulin sensitivity via osteocalcin metabolism: a placebo-controlled trial  
H.J. Choi, J. Yu, H. Choi, J.H. An, S.W. Kim, K.S. Park, H.C. Jang, S.Y. Kim, C.S. Shin

## Online Letters: Comments and Responses

**e148** Comment on: Sun et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-Year Medalist Study. *Diabetes Care* 2011;34:968–974

B.N. Conway, J.D. Maynard, T.J. Orchard

**e149** Response to comment on: Sun et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-Year Medalist Study. *Diabetes Care* 2011;34:968–974

J.K. Sun, H.A. Keenan, V.M. Monnier, L.P. Aiello, G.L. King

**e150** Comment on: Gaillard et al. HDL dysfunctionality (paraoxonase) is worse in nondiabetic, postmenopausal African American than in white women. *Diabetes Care* 2011;34:e19

A. Viktorinova, S. Kinova

**e151** Response to comment on: Gaillard et al. HDL dysfunctionality (paraoxonase) is worse in nondiabetic, postmenopausal African American than in white women. *Diabetes Care* 2011;34:e19

T. Gaillard, S. Parthasarathy, K. Osei



The American Diabetes Association (ADA) is the nation's leading voluntary health organization supporting diabetes research, information, and advocacy. Its mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. ADA is the leading publisher of comprehensive diabetes information. Its huge library of books and periodicals covers every aspect of diabetes and diabetes care.

**To join ADA:** Call 1-800-806-7801 or visit [www.diabetes.org/membership](http://www.diabetes.org/membership)

**To subscribe to ADA journals:** Call 1-800-DIABETES or go to [www.diabetesjournals.org](http://www.diabetesjournals.org)

**To order ADA books:** Call 1-800-232-6733 or visit <http://store.diabetes.org>

**To access ADA's library of professional resources:** Go to [professional.diabetes.org](http://professional.diabetes.org)

**For more information about diabetes or ADA programs and services:** Call 1-800-DIABETES. E-mail: AskADA@diabetes.org or visit [www.diabetes.org](http://www.diabetes.org)

**To locate an ADA/NCQA Recognized Provider of quality diabetes care in your area:** Visit <http://web.ncqa.org>

**To join the fight to increase funding for diabetes research, end discrimination, and improve insurance coverage:** Call 1-800-DIABETES or visit [www.diabetes.org/advocate](http://www.diabetes.org/advocate)

**To find out how you can get involved with the programs in your community:** Call 1-800-DIABETES or visit [www.diabetes.org/in-my-community](http://www.diabetes.org/in-my-community)

**To find out about important research regarding diabetes:** Go to [www.diabetes.org/news-research](http://www.diabetes.org/news-research)

**To make a donation or memorial contribution:** Call 1-800-DIABETES or visit [www.diabetes.org/donate](http://www.diabetes.org/donate)